Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA let-7g alleviates atherosclerosis via the targeting of LOX-1 in vitro and in vivo.
|
28535009 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent results demonstrated that LOX-1, a receptor associated with obesity and atherosclerosis, is overexpressed in advanced and metastatic prostate cancer.
|
29107109 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hereby provide an updated overview of role of LOX-1 in atherosclerosis and associated vascular diseases, with an aim to highlighting the potential of LOX-1 as a novel theranostic tool for cardiovascular disease prevention and treatment.
|
30381837 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The lectin-like oxidized LDL receptor 1 (LOX-1) is a key player in the development of atherosclerosis.
|
30819724 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unveiling LOX-1 receptor interplay with nanotopography: mechanotransduction and atherosclerosis onset.
|
23355954 |
2013 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We thus propose that CD36, CLA-1 and CD68, but not SR-A and LOX-1, may play crucial roles in the progression of macrophages to foam cells, which is a key step for the initiation of atherosclerosis.
|
12238639 |
2002 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Both OLR1 and PCSK9 genes are associated with atherosclerosis, cardiovascular disease and ischemic stroke.
|
26666837 |
2015 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been well confirmed ox-LDL plays key roles in the development of atherosclerosis via binding to LOX-1 and inducing apoptosis in vascular endothelial cells.
|
24252910 |
2013 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that antagonism between SRSF1 and SRSF2/HMGA1, and differential recognition of their regulatory motifs depending on the identity of the rs3736234 polymorphism, influence OLR1 exon 5 inclusion and the efficiency of Ox-LDL uptake, with potential implications for atherosclerosis and coronary disease.
|
25904137 |
2015 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article we focus on the different mechanisms for regulation, signaling and the various effects of LOX-1 in contributing to atherosclerosis.
|
31336709 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lectin-like oxLDL receptor-1 (LOX1) is one of the major contributors of oxLDL uptake and degradation in macrophages, which leads to foam cell formation and the development of atherosclerosis.
|
28941610 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The lectin-like oxidised LDL receptor-1 (OLR1) gene encodes a scavenger receptor implicated in the pathogenesis of atherosclerosis.
|
22347434 |
2012 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a model of cellular transformation, the MCF10A ER-Src, inhibition of LOX-1 gene reduces NF-kB activation and the inflammatory and hypoxia pathways, suggesting a mechanistic connection between cellular transformation and atherosclerosis.
|
29462603 |
2018 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, Hcy-induced atherosclerosis was closely associated with induced hypomethylation status in the blood vessel, and this process was partially mediated by LOX-1 DNA methylation.
|
24938465 |
2014 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The human oxidised low-density lipoprotein receptor 1 (OLR1) gene is a functional candidate for atherosclerosis.
|
16251892 |
2006 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Many naturally occurring compounds have been shown to modulate LOX-1 expression and atherosclerosis.
|
29737246 |
2019 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The up-regulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), encoded by the OLR1 gene, plays a fundamental role in the pathogenesis of atherosclerosis.
|
26542080 |
2016 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the basis of the obtained results, in the atherosclerosis mice treated with the agomir of miR-9 and siRNA against OLR1, the p38-mitogen-activated protein kinase (p38MAPK) pathway was inhibited; levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol, tumor necrosis factor-α, interleukin-6, and vascular endothelial growth factor were reduced, but the high-density lipoprotein cholesterol level was increased, along with decreased vulnerable atherosclerotic plaque area and enhanced vascular remodeling.
|
31571264 |
2020 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results indicate that LPS up-regulates LOX-1, at least in part through activation of the Erk1/2 signaling pathway, followed by augmented cellular oxLDL uptake, thus highlighting a critical role of TLR4-mediated aberrant LOX-1 signaling in the pathogenesis of atherosclerosis.
|
25348362 |
2015 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations provide clinical support to experimental studies implicating LOX -1 in atherosclerosis and its possible role as target for cardiovascular intervention.
|
30744454 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies have revealed that endothelial lectin‑like ox‑LDL receptor‑1 (LOX‑1) and long intergenic noncoding RNA p21 (lincRNA‑p21) may serve as therapeutic targets for atherosclerosis and associated cardiovascular disorders.
|
28983628 |
2017 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Literature data demonstrate a protective role of LOXIN in pathologies correlated with LOX-1 overexpression such as atherosclerosis and tumors.
|
28146073 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexarelin decreased the aortic expressions of CD68 and LOX-1 which were elevated in the AS group.
|
31386895 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cryptotanshinone, an orally bioactive herbal compound from Danshen, attenuates atherosclerosis in apolipoprotein E-deficient mice: role of lectin-like oxidized LDL receptor-1 (LOX-1).
|
25572313 |
2015 |